Haemonetics Corporation updated revenue guidance for the year 2023. For the period, The Company updated its previous fiscal 2023 GAAP total revenue growth guidance from 8% - 11% to 12% - 15% and its fiscal 2023 organic revenue growth guidance as follows: total revenue of 15% - 18% against previous guidance of 10% - 14%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.66 USD | +1.67% | +5.03% | +2.51% |
Apr. 04 | Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge | MT |
Apr. 04 | Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.51% | 4.45B | |
-2.92% | 185B | |
-3.80% | 105B | |
-5.48% | 66.59B | |
+11.22% | 54.66B | |
+16.74% | 47.78B | |
+4.06% | 41.26B | |
+4.56% | 26.95B | |
+1.64% | 26.37B | |
+12.96% | 24.8B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Updates Revenue Guidance for the Year 2023